
    
      Primary Objectives:

      1) Assess whether the rate of clinical benefit is sufficiently high to merit promise for
      further study

      Secondary Objectives:

        1. Characterize the 6-month progression-free survival rate

        2. Assess whether the treatment yields a reasonably safe and tolerable profile
    
  